G-protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that modulate biological function by initiating cellular signalling in response to chemically diverse agonists. Despite recent progress in the structural biology of GPCRs 1 , the molecular basis for agonist binding and allosteric modulation of these proteins is poorly understood. Structural knowledge of agonist-bound states is essential for deciphering the mechanism of receptor activation, and for structure-guided design and optimization of ligands. However, the crystallization of agonist-bound GPCRs has been hampered by modest affinities and rapid off-rates of available agonists. Using the inactive structure of the human b 2 adrenergic receptor (b 2 AR) as a guide, we designed a b 2 AR agonist that can be covalently tethered to a specific site on the receptor through a disulphide bond. The covalent b 2 AR-agonist complex forms efficiently, and is capable of activating a heterotrimeric G protein. We crystallized a covalent agonist-bound b 2 AR-T4L fusion protein in lipid bilayers through the use of the lipidic mesophase method 2 , and determined its structure at 3.5 Å resolution. A comparison to the inactive structure and an antibodystabilized active structure (companion paper 3 ) shows how binding events at both the extracellular and intracellular surfaces are required to stabilize an active conformation of the receptor. The structures are in agreement with long-timescale (up to 30 ms) molecular dynamics simulations showing that an agonistbound active conformation spontaneously relaxes to an inactivelike conformation in the absence of a G protein or stabilizing antibody.
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G-protein-coupled receptors (GPCRs) are eukaryotic integral membrane proteins that modulate biological function by initiating cellular signalling in response to chemically diverse agonists. Despite recent progress in the structural biology of GPCRs 1 , the molecular basis for agonist binding and allosteric modulation of these proteins is poorly understood. Structural knowledge of agonist-bound states is essential for deciphering the mechanism of receptor activation, and for structure-guided design and optimization of ligands. However, the crystallization of agonist-bound GPCRs has been hampered by modest affinities and rapid off-rates of available agonists. Using the inactive structure of the human b 2 adrenergic receptor (b 2 AR) as a guide, we designed a b 2 AR agonist that can be covalently tethered to a specific site on the receptor through a disulphide bond. The covalent b 2 AR-agonist complex forms efficiently, and is capable of activating a heterotrimeric G protein. We crystallized a covalent agonist-bound b 2 AR-T4L fusion protein in lipid bilayers through the use of the lipidic mesophase method 2 , and determined its structure at 3.5 Å resolution. A comparison to the inactive structure and an antibodystabilized active structure (companion paper 3 ) shows how binding events at both the extracellular and intracellular surfaces are required to stabilize an active conformation of the receptor. The structures are in agreement with long-timescale (up to 30 ms) molecular dynamics simulations showing that an agonistbound active conformation spontaneously relaxes to an inactivelike conformation in the absence of a G protein or stabilizing antibody.
The relationship between agonist binding to GPCRs and the conformational changes that facilitate G protein binding and activation remains largely unknown. Characterization of GPCR activation at a molecular level has been driven by a combination of X-ray crystal structure analysis and spectroscopic approaches. Rhodopsin has served as a prototype GPCR for biophysical studies, given its ready availability and superior stability. Crystal structures have been obtained for the inactive dark state with inverse agonist 11-cis-retinal covalently bound 4, 5 , as well as the active state mimetic low-pH opsin lacking the retinal chromophore 6, 7 . Opsin differs from rhodopsin by outward rigid-body movements of transmembrane helices (TMs) 5 and 6 at the cytoplasmic G protein binding surface. For other GPCRs, which respond to diffusible ligands, structural information has proven more difficult to obtain. Fluorescence spectroscopy studies show that activation of the b 2 AR by diffusible ligands can follow multiple pathways, with a complex energy landscape of receptor conformations 8 . This multitude of accessible conformations has probably contributed to the difficulty in obtaining crystal structures of nonrhodopsin GPCRs.
Inactive state crystal structures of the b 2 AR, b 1 AR, and A 2A adenosine receptor have been solved over the past several years with the aid of protein engineering techniques 1 , but agonist-bound structures for these proteins have yet to be reported. Like many GPCRs, the b 2 AR has two agonist affinity states: a low affinity state in the absence of cognate G protein, and a high affinity state in the presence of G protein. This observation indicates that agonists can bind to two distinct receptor conformations. A more complete understanding of the processes of agonist binding and activation requires structures of both high and low affinity states. The high affinity state is challenging because a receptor G protein complex is unstable in detergent solutions required for purification of both GPCRs and heterotrimeric G proteins. In a companion paper 3 , we describe the use of a conformationally selective camelid antibody (nanobody, Nb80) with G-protein-like properties to obtain a structure of a high-affinity agonist-bound conformation. Obtaining a structure of the low affinity state is also challenging because of the relatively rapid association and dissociation rates of commercial b 2 AR agonists. Inspired by the covalent retinal-rhodopsin system, we proposed that the ability to crystallize an agonist-bound GPCR would be enhanced by chemically crosslinking ligand and receptor, preferably in a manner that would not inhibit conformational freedom and the capacity to activate a G protein.
Our design strategy for a covalent b 2 AR agonist was to combine a b-adrenergic agonist core (procaterol) and a reactive chemical group that could be targeted to a specific residue on the receptor. Using the structure of the carazolol-bound b 2 AR as a template (Fig. 1a) , a flexible linker was added to bridge these two components such that the covalent attachment would not inhibit binding of the agonist core or conformational flexibility of the transmembrane helices. Biochemical precedent for this strategy came from the covalent labelling reagent BABC (Fig. 1b) , in which an electrophilic group appended to the carazolol ligand core was determined to react with His 93 2.64 at the extracellular end of TM2 (ref. 9; Ballesteros-Weinstein numbering 10 used in superscript). For crosslinking, we chose the reaction between a free cysteine on the receptor (introduced at position 93) and a ligand disulphide moiety, based on the mild and proximity-dependent 'tethering' approach that has proven broadly applicable to different protein targets including GPCRs
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. The designed covalent b agonist FAUC50 (Fig. 1b) was synthesized in enantiomerically pure form 12, 13 , along with the noncovalent analogue FAUC72 (Fig. 1b, Supplementary  Fig. 1 and Supplementary Information) for use in control experiments.
Incubation of compound FAUC50 with mutant H93C receptor led to efficient and irreversible blocking of radioligand binding ( Supplementary Fig. 2, Supplementary Information) . We sought to determine whether the tethered FAUC50-b 2 AR H93C complex is capable of activating a G protein. Wild-type and mutant receptor were reconstituted into high density lipoprotein (HDL) particles 14 , and then incubated with ligand alone or ligand followed by an excess of the high-affinity inverse agonist ICI-118,551. Heterotrimeric Gs protein was then added to the particles, and activation was observed by measuring GTPc 35 S binding to the Gs a subunit. Figure 1c shows that the inverse agonist treatment prevented agonist-induced G protein activation by the wild-type receptor. However, excess ICI-118,551 is unable to reverse FAUC50-induced coupling in the case of b 2 AR
H93C
. The noncovalent analogue FAUC72 is displaced by the inverse agonist for both wild-type and H93C mutant receptors. From these experiments we conclude that FAUC50 not only reacts efficiently with Cys 93 to form a covalent complex, but this complex is also capable of activating a G protein.
We were motivated to develop a covalent agonist by our inability to produce diffraction-quality crystals of the previously described b 2 AR-T4 lysozyme chimaera (b 2 AR-T4L) in complex with available noncovalent agonists. In contrast, the purified FAUC50-b 2 AR H93C T4L complex readily yielded diffraction-quality crystals in lipidic mesophases 15 . We overexpressed the mutant receptor in Sf9 insect cells, purified the protein to homogeneity using immunoaffinity and ligand-affinity chromatography, and introduced the FAUC50 ligand during a subsequent chromatography step. Using a cholesterol-doped monoolein cubic phase and robotic in meso technology 16 , we obtained 50 3 15 3 5 mm blade-shaped crystals ( Supplementary Fig. 3 ) that diffracted to 3.5 Å . Combining diffraction data from 19 microcrystals (Supplementary Table 1) , we solved the agonist-bound structure by molecular replacement using the coordinates of carazolol-bound b 2 AR-T4L
17 as a search model. The packing of protomers in the orthorhombic crystals is distinct from previous crystals of b 2 AR-T4L fusion proteins. However, the orientation of T4L relative to the receptor closely resembles the original carazolol-bound structure (PDB ID 2RH1). An omit map at the ligand binding site reveals clear electron density for the agonist ( Supplementary Fig. 4) , and the refined structure shows prominent features expected from adrenergic receptor Fig. 2a, left) . The crystal structure of the covalent agonist-bound receptor in a lipidic mesophase does not show the conformational changes near the cytoplasmic surface associated with G protein binding, as observed in the nanobody-stabilized agonist complex (Fig. 2b) . This was surprising given that the covalent agonist-bound receptor activates Gs (Fig. 1c) and the T4L fusion does not interfere with agonist-induced conformational changes detected with a fluorescent probe at the end of TM6 (ref. 17 ). This result implies that even an agonist with zero dissociation inefficiently stabilizes an active conformation of the b 2 AR in a lipid bilayer environment, consistent with a higher stability of the inactive carazololbound conformation. Nevertheless, allosteric communication between the ligand-binding pocket and the cytoplasmic G-protein-binding surface is a fundamental feature of GPCRs, exemplified by agonist-induced G protein stimulation and G-protein-induced high-affinity agonist binding 14 . For the b 2 AR, we can now compare an agonist-bound structure to that of a nanobody-stabilized active state mimetic (see companion paper
3 ), to better understand conformational changes associated with activation. The superposition in Fig. 2b shows that agonist binding alone is insufficient to stabilize an active conformation at the cytoplasmic surface, with the requisite outward movement of TM5 and TM6. The largest differences proximal to the ligandbinding pocket in the nanobody-stabilized active conformation involve movement of Ile 121 3.40 away from Pro 211 5.50 and into space occupied by Phe 282 6.44 in the inactive state (Fig. 2c, middle) . The concomitant outward movement of Phe 282 6.44 is accompanied by subtle backbone torsion changes distributed through TM6 that cause the cytoplasmic half of TM6 to be redirected outward, similar to its orientation in activated opsin 6,7 . In the binding pocket, the most significant difference between the two agonist-bound structures and the carazolol-bound b 2 AR are in the hydrogen bonding contacts with 
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Ser 203
5. 42 and Ser 207 5.46 on TM5 (Fig. 2a) . However, only in the nanobody-stabilized structure are these differences coordinated with further changes towards the cytoplasmic surface of the molecule (Fig. 2b and c, middle) .
To determine whether an agonist-bound receptor would sustain a stable active conformation in the absence of a cytoplasmic binding partner, we initiated an unbiased molecular dynamics (MD) simulation of the receptor from the nanobody complex structure, but with the nanobody removed (Fig. 3a) . In the first several microseconds of simulated time, the intracellular ends of TM5 and TM6 showed high mobility ( Supplementary Fig. 5 ), drifting by as much as 5 Å from their crystallographic positions. After approximately 11 ms, the agonistbound receptor spontaneously transitioned to a more rigid conformation resembling the inactive, carazolol-bound structure and the covalent agonist-bound structure (superposition in Fig. 3b ), which remained stable for the remainder of the 30-ms simulation (Fig. 3a , top, and Supplementary Fig. 6 ). In particular, TM5 and TM6 reverted to the positions they adopt in the inactive structure, as did a number of side chains, including Ile 121 3. 40 and Phe 282 6. 44 ( Fig. 3a, bottom) . Following the transition, the TM3-TM6 ionic lock was usually intact, as observed previously in simulations initiated from the inactive structure 19 .
Although this 30-ms simulation is an order of magnitude longer than any previously published atomistic simulation of a membrane protein, the transition to an inactive-like conformation took place more quickly than the millisecond timescales observed experimentally for adrenergic receptor activation -two conserved residues whose protonation states have been suggested to change upon receptor activation 21, 22 -showed similar behaviour ( Supplementary Fig. 7 ). In the dynamic conformational equilibrium of a GPCR that links diffusible agonist binding and G protein association, the energies of different states reflect both the ligand binding energies and the conformations of the receptor and its binding partners. This can be depicted in a hypothetical energy landscape of the b 2 AR as shown in Fig. 3c , where R, R9, R99 and R* represent members of the ensemble of receptor conformations along an activation pathway. The constitutive activity displayed by the b 2 AR implies that the energy differences and barriers between inactive (R) and active (R*) conformations are low enough to allow a significant population of active state receptors even in the absence of agonist. Agonist binding decreases the energy difference and thus increases the population of receptors in an active conformation; however, the inactive state is still the most stable FAUC50   TM3   TM7  TM5  TM6   S203   S207   S204  N312   D113 Y316   TM3  TM4   TM2   F290   F193   W109   W286   TM4   TM1   TM2   A200   V117   V114  S203   S207   S204  N312   D113  Y316   F290   F193  W109   W286   A200   V117   V114  S203   S207   S204  N312   D113 Y316   F290   F193   W109   W286   A200   V117   V114   TM5   TM3   TM7  TM5  TM6   TM4   TM1  TM2   TM3   TM7  TM5   TM6   TM4   TM1   TM2   H8  H8  H8   H95C   Pro 211  Phe 282  Phe 282  Ile 121  Ile 121   c   TM5  TM6  TM3   TM5  TM6  TM3  TM3   TM6 
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conformation. Our crystallographic studies and MD simulations are compatible with fluorescence lifetime experiments on the purified receptor, demonstrating that saturating concentrations of a full agonist are incapable of pushing the b 2 AR conformational equilibrium towards a homogenous active state 23 . These results indicate that binding energy from a G protein or nanobody interaction is required to stabilize conformational changes such as those observed in the vicinity of Ile 121 3. 40 and Phe 282 6.44 in the active state (Fig. 2c) . Alternative biophysical approaches such as NMR 24, 25 and further molecular dynamics simulations will be crucial to understand these transitions and identify potential pathways and intermediates that are compatible with these structures.
METHODS SUMMARY
Synthetic chemistry methodology to generate FAUC50 and FAUC72 is described in Supplementary Information. Protocols for radioligand binding and Gs activation assays to characterize ligands are described in Methods. Crystallization. FAUC50-b 2 AR H93C T4L was expressed, purified and crystallized as described in Methods. The receptor was crystallized in a cholesterol-doped (10%) monoolein cubic phase overlaid with precipitant in glass sandwich plates. Optimized precipitant consisted of 24-27%(v/v) PEG 400, 200 mM Li 2 SO 4 , 4%(v/v) DMSO, 3.5%(v/v) 1,4-butanediol, 100 mM MES pH 6.7. After 3-5 days of growth, crystals were harvested after adding an excess of precipitant solution for cryoprotection, and flash-frozen in liquid nitrogen.
Data collection, structure solution and refinement. Diffraction data were collected at beamline 23-ID (GM/CA-CAT) of the Advanced Photon Source, using a 10 mm diameter collimated microbeam. Oscillation data were measured in 1.0u frames with 10 s or 25 s exposures using 23 or 53 attenuated beam, respectively. The complete data set consisted of 106u of data from 19 crystals. The structure of FAUC50-b 2 AR H93C T4L was solved by molecular replacement, and refined by group B factor and TLS refinement. Full details are provided in Methods. Molecular dynamics. All-atom classical molecular dynamics simulations with explicitly represented lipids and water were performed using the CHARMM force field 26 on Anton 27 , a special-purpose computer that accelerates such simulations by orders of magnitude; details are provided in the Methods. 
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G protein activation assay with ICI-118,551 reversal. Wild-type b2AR or b2AR H93C were purified in unliganded form 28 . Samples of these receptors were reconstituted into rHDL (recombinant high density lipoprotein) particles as described 14 . For GTPcS binding assay, receptor-rHDL particles were preincubated with 5 mM FAUC50 or 5 mM FAUC72 for 4 h at 4 uC. Samples were diluted 20-fold into binding buffer and split. Half of the samples were used in GTPcS binding assays without ICI-118,551 competition, while the other half was incubated with 6 mM ICI-118,551 at room temperature for 1 h with shaking. Control samples of receptor-rHDL particles with no ligand, 10 mM isoproterenol, or 10 mM ICI-118,551 were also prepared. Purified Gs heterotrimer 29 was added to each sample and incubated for 10 min at 23 uC. The final concentrations of reconstituted receptor and Gs were 100 nM and 600 nM, respectively. GTPcS binding reactions were initiated by the addition of 0.4 nM [ GTPcS was removed by rapid filtration of the particles using glass fibre filters. Filterbound radioactivity was determined by liquid scintillation counting using a Beckman LS6000 scintillation counter. Data shown in Fig. 1c are from three independent experiments each performed in triplicate. Purification of b 2 AR H93C T4L. The construct used for crystallography consisted of the b2AR-T4L fusion protein 17 with the following modifications: a TEV (tobacco etch virus) protease site was inserted after residue 23 of the human b2AR sequence; Histidine 93 was mutated to cysteine; the construct was terminated by a 63His tag after residue 348 of human b2AR. This construct was cloned into the baculovirus transfer vector pVL1392, and the resulting vector was used to make a high-titre baculovirus stock using the Bestbac system (Expression Systems). The b 2 AR H93C T4L receptor was expressed in Sf9 insect cell cultures infected with this baculovirus, and Sf9 membranes were solubilized as described 17 . Purification was achieved using M1 Flag affinity chromatography (Sigma), functional alprenolol-Sepharose chromatography 30 , and a second M1 chromatography concentrating step. While the receptor was still bound to the second M1 Flag column, bound alprenolol was washed out and replaced with the covalent ligand using 3 h of washing with 15 column volumes of buffer containing 30 mM FAUC50 (tenfold total molar excess over receptor). Likewise, the dodecylmaltoside detergent used in all previous steps was exchanged for 0.1% (w/v) MNG-3 amphiphile 31 . Covalent agonist-bound and detergent-exchanged b2AR
H93C
T4L was eluted in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.1% (w/v) MNG-3, 30 mM FAUC50. In contrast to previously published protocols, receptor was not alkylated before alprenolol-Sepharose chromatography. Instead, receptor was alkylated after agonist exchange by treatment with 2 mM iodoacetamide for 30 min at 4 uC. Incubation of the eluate with AcTEV protease (Invitrogen) succeeded in removing the N terminus of the receptor (23 amino acids plus TEV site, leaving a glycine scar preceding residue 24), as verified by SDS-PAGE analysis. The sample at this stage was further purified and concentrated using Ni chelating chromatography, taking advantage of the C-terminal 63His tag. Receptor was bound to a 0.7-ml column Ni-Sepharose column, and eluted in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.1% (w/v) MNG-3 and 30 mM FAUC50, 200 mM imidazole. Finally, the receptor was concentrated to 50 mg ml 21 with a 100 kDa cutoff Vivaspin concentrator (Vivascience). Crystallization. Purified FAUC50-b 2 AR H93C T4L was crystallized using the in meso method 2 . Cubic phase reconstitution consisted of two parts 50 mg ml 21 receptor and three parts molten lipid mixture (10:1 monoolein:cholesterol by mass, lipids purchased from Sigma). Note that cholesterol is required for successful crystallization, and one cholesterol molecule is included in the refined model. Aqueous and lipid components were combined at room temperature using a syringe mixing apparatus 32 . Crystallization experiments in glass sandwich plates, set up by either by hand or using an in meso robot 16 , consisted of 30-50 nl cubic phase overlaid with 800 nl precipitant. Precipitant conditions producing diffraction quality crystals were identified by screening around previous conditions 17 , and testing additives and alternative buffers. Final optimized conditions consisted of 24-27%(v/v) PEG 400, 200 mM Li 2 SO 4 , 4%(v/v) DMSO, 3.5%(v/v) 1,4-butanediol, 100 mM MES pH 6.7. Crystals grew at 20 uC to a maximum size of 50 3 15 3 5 mm 3 within 3 to 5 days (see Supplementary Fig. 3, Supplementary Materials) . For harvesting and cryocooling, exposed crystallization drops were overlaid with an excess of precipitant solution, and cryoloops (MiTeGen) containing single crystals were flash-frozen in liquid nitrogen. Data collection and processing. Diffraction data were collected at beamline 23-ID of the General Medicine and Cancer Institutes Collaborative Access Team (GM/ CA-CAT) of the Advanced Photon Source, Argonne, Illinois, USA. All data was acquired using a 10-mm diameter collimated microbeam. Attenuated 1.0u rotation images were used to locate and centre crystals within the opaque mesophase in each cryoloop. Oscillation data were measured in 1.0u frames with 10 s or 25 s exposures using 23 or 53 attenuated beam, respectively. Significant radiation damage caused decay in the signal that prevented merging more than the first 5-10u of oscillation data from each crystal. A total of 106u of data from 19 crystals were integrated with Mosflm 33 and merged with Scala
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. Structure solution and refinement. Molecular replacement to obtain initial phases was performed with the program Phaser 35 . The separated structures of the receptor and T4L components of the high-resolution carazolol-bound b 2 AR structure (PDB ID 2RH1 with all non-protein atoms removed), were used as search models. The model was refined in Phenix 36 and Buster
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, using group B factor refinement (one B factor per residue) followed by TLS refinement (using two TLS groups, one for the receptor and one for T4L). Refinement statistics are given in Supplementary Table 1 of Supplementary Information. The crystallographic data was strongly anisotropic, as seen in the anisotropic B factor corrections; however, the electron density was clear enough for the placement of side chains. Although there was clear electron density present for the agonist (see omit map in Supplementary Fig. 4, Supplementary Information) , we did observe a small discontinuity at the end of the linker connecting to Cys 93. This discontinuity could arise from flexibility of the polymethylene component of the linker, as well as potential radiation damage 38 localized to the disulphide bond. As a control, we carried out refinement in which the ligand was modelled as a non-covalent species without a disulphide connection to the receptor. No significant differences in final model R/R free or 2Fo 2 Fc and Fo 2 Fc electron density maps were observed. Molecular dynamics simulations. In all simulations, b 2 AR was embedded in a hydrated lipid bilayer, with all atoms, including those in the lipids and water, represented explicitly. The BI-167107-bound b 2 AR simulations were initiated with the receptor and ligand in the conformation of the b 2 AR-Nb80 crystal structure (companion paper 3 ), with the nanobody (Nb80) removed. The carazolol-bound b 2 AR simulations were initiated with the receptor and ligand in the conformation of the high-resolution carazolol-bound crystal structure 17 . Both crystal structures were determined using a b 2 AR-T4L fusion protein, in which intracellular loop 3 (ICL3) of the receptor was replaced by T4 lysozyme (although the T4L was not resolved in the BI-167107-bound nanobody complex structure). We omitted the T4L in all simulations. Experimentally, removal of the bulk of ICL3 by partial tryptic digest does not seem to affect receptor function 39 . Production simulations were performed on Anton 27 , a special-purpose computer designed to accelerate standard molecular dynamics simulations by orders of magnitude relative to the previous state of the art. Prior to production simulation, systems were equilibrated using Desmond 40 on a commodity cluster, according to the protocol described below.
Hydrogens were added to the crystal structures of carazolol-bound b 2 AR (b 2 AR-Cz; PDB ID 2RH1) and b 2 AR-Nb80/BI-167107 (companion paper 3 ) using Maestro (Schrödinger) as described previously 19 . T4L and Nb80 were deleted, and chain termini were capped with neutral groups (acetyl and methylamino).
All titratable residues other than Glu 122 41 . On the other hand, neutralization of Asp 79 2.50 in b 2 AR by mutation to asparagine uncouples agonist binding from G protein activation 43 , and a recent study suggested that Asp 79 may be deprotonated upon activation b 2 AR residues that were truncated or not resolved in the crystal structures were omitted from the simulations. In particular, N-terminal residues 1-28, C-terminal residues 343-413, and ICL3 residues 231-262 were omitted from the carazololbound system, whereas N-terminal residues 1-22, C-terminal residues 345-413 and ICL3 residues 228-265 were omitted from the BI-167107-bound system. Both simulations included a glutamate at position 187, reflecting an Asn 187 Glu mutation made in both crystallization constructs to eliminate a glycosylation site.
We prepared the carazolol-bound Ash 79/Asp 130 b 2 AR system following our previously described protocol 19 , and the other systems according to an updated protocol (details below). We do not expect the differences in the simulation setup LETTER RESEARCH
